eligibility_summary
Adults ≥18 with R/R AML (refractory after standard induction or HMA±ven/LDAC, or ≥4 HMA cycles, or relapse with ≥5% blasts after CR/CRh/CRi), ECOG 0–1, suitable donor, adequate organs (Cr<2, bili<2, AST/ALT≤5×ULN). Exclude APL, active CNS disease, O2 sat<90%, recent clofarabine/cladribine, prohibited steroid/chemo timing, major CV disease, uncontrolled infection, HIV/HBV/HCV, active 2nd cancer, live vaccine, pregnancy, other risks. Prior allo-HSCT allowed if >3 mo and no systemic GVHD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: ADCLEC.syn1 CAR T cells—autologous, gene‑modified T cells with a cooperative/dual CAR recognizing the AML antigens ADGRE2 (EMR2) and CLEC12A (CLL‑1), antigen engagement activates T‑cell signaling and cytotoxic killing of leukemic blasts/LSCs while aiming to spare normal myeloid cells. Dose escalation: 10–450×10^6 cells. Conditioning chemotherapy: fludarabine (purine analog antimetabolite inhibiting DNA synthesis) and cyclophosphamide (alkylating agent causing DNA crosslinks) for lymphodepletion to support CAR T expansion. Targets: AML cells expressing ADGRE2/CLEC12A.